Abstract: A bone conduction hearing-aid unit that is entirely embedded under a scalp. The bone conduction hearing-aid unit includes a vibration generating device configured to generate vibration, and an anchor fixed to a skull and configured to transmit the vibration to the skull. The vibration generating device is detachably fixed to the anchor.

Abstract: [Problem to be solved by the invention] The purpose of the present invention is to provide a competitive immunochromatographic analysis method and immunochromatographic sensor using said analysis method capable of intuitively displaying a molecular concentration of a substance to be measured and facilitating visual judgement of the molecular concentration.

Abstract: A vibration-driven energy harvesting device includes a vibration-driven energy harvesting element that generates power according to vibrations of an electrode; an output unit that, when connected to a load resistor, extracts power generated by the vibration-driven energy harvesting element; a judgment unit that judges whether or not a power value of the power is greater than a predetermined threshold value; a determination unit that determines an input impedance of the output unit based on a judgment result obtained by the judgment unit; and an adjustment unit that adjusts the input impedance of the output unit according to a determination made by the determination unit.

Abstract: A composition for decomposition of trypsin or TMPRSS2 containing, as an active ingredient, bacteria that have 00502 protein, or a protein having 30% or higher sequence identity with an amino acid sequence of the 00502 protein and having a trypsin-binding ability; or bacteria that have 00509 protein, or a protein having 30% or higher sequence identity with an amino acid sequence of the 00509 protein and having a trypsin-binding ability.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for inflammatory disease including a compound or a salt thereof, or a solvate thereof, the compound represented by a formula (1): [where each sign is defined as described in the description] as an active ingredient.

Abstract: An electroencephalogram decision system determines, when finding electroencephalogram information representing an electroencephalogram obtained by an electrode unit placed on a region of interest that forms part of a subject's head satisfying a predetermined condition, that a target electroencephalogram, which is an electroencephalogram with a characteristic variation, should have been produced. The predetermined condition is selected from of detection conditions including a first type of condition and a second type of condition. The first type of condition specifies that a decision should be made, based on a component falling within a single frequency band included in the electroencephalogram represented by the electroencephalogram information, whether or not the target electroencephalogram has been produced.

Abstract: The present invention is to provide a means for promoting muscle regeneration from muscle damage. According to the present invention, the muscle regeneration from muscle damage is promoted by using a compound having histamine H receptor agonist activity (except for histamine) or a salt thereof is used as an active ingredient.

Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: The present invention provides a therapeutic agent for an immune/inflammatory disease comprising an anti-human TIGIT antibody, which activates a suppressive immune checkpoint molecule (TIGIT), as an active ingredient. Also, provided is an antibody having the following characteristics a) and b): a) the third CDR of heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4 b) the third CDR of light chain variable region comprises the amino acid sequence of SEQ ID NO: 6.

Abstract: A finger exerciser includes: a frame on which a palm of a subject to be put; a movable section; a first fixing element; and a second fixing element. The movable is configured to move a first finger group of a subject. The first fixing element is configured to fix a position of the first finger group to the movable section. The second fixing element is configured to fix a position of a second finger group to the frame and has a band-like member including at least two attachment parts apart from each other in a longitudinal direction of the band-like member. The band-like member is attached to the frame at the attachment parts and includes a holder whose location to the frame is changeable. The band-like member is configured to hold the second finger group in a state where the band-like member is attached to the frame.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: An object of the present invention is to provide, for example, a more practical wound healing accelerator that more effectively accelerates wound healing. More specifically, a feature of the present invention is to provide, for example, a more practical wound healing accelerator that is easily obtained in a larger amount than that of peripheral blood platelet and has a better wound healing effect than that of peripheral blood platelet. The present invention employs a platelet-like cell population coexpressing one or more platelet surface markers and one or more mesenchymal cell surface markers. A wound healing accelerator containing the platelet-like cell population is a more practical wound healing accelerator that more effectively accelerates wound healing. The platelet-like cell population is easily obtained in a larger amount than that of peripheral blood platelet and has a better wound healing effect than that of peripheral blood platelet.

Abstract: A subject of the present invention is to provide an anti AQP3 antibody specifically recognizing the extracellular domain of aquaporin 3 (AQP3), which is one type of a water channel protein. By selecting a monoclonal antibody which specifically binds to an oligopeptide included in loop C as one of the extracellular domains of AQP3, an anti AQP3 antibody that is desired in the present invention is provided. An anti AQP3 monoclonal antibody of the present invention can directly bind, from the outside of a cell, to AQP3 present in a cell membrane. Furthermore, as an anti AQP3 monoclonal antibody of the present invention can have an inhibitory activity, the function of permeating a low molecular weight molecule or the like, which is carried by AQP3, can be suppressed.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: The present invention provides a drug for treating and/or preventing enteritis and/or hepatitis, said drug containing D-amino acid as an active ingredient. In addition, the present invention provides a food composition for suppressing enteritis and/or hepatitis, said composition containing D-amino acid as an active ingredient. In addition, the present invention provides a method for assisting diagnosis of enteritis and/or hepatitis in a subject, said method using the amount of D-amino acid in the intestinal tract as an indicator.

Abstract: The present invention addresses the problem of providing: a fusion protein or conjugated protein having excellent cell membrane permeability, containing a partial peptide derived from human, and suitable for intracellular delivery; an intracellular delivery carrier comprising such a fusion protein or conjugated protein; a partial peptide; a cell membrane permeation enhancer comprising the partial peptide; DNA; and a vector. The fusion protein or conjugated protein has a partial peptide comprising at least seven consecutive amino acid residues of an amino acid sequence encoded by a predetermined DNA, and a ligand directly or indirectly bound to the partial peptide and having the capability of binding to cell surfaces. The ligand is preferably an antibody. The intracellular delivery carrier comprises the fusion protein or conjugated protein. The cell membrane permeation enhancer comprises the partial peptide.

Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.

Abstract: A middle ear sound transmission characteristics evaluation system includes a probe; a measuring probe that includes an actuator that vibrates the probe and a force sensor that outputs a voltage in accordance with a reaction force exerted to the actuator when a tip of the probe is brought into contact with ossicles; an electrode that is installed on or near a round window and detects a potential value of a cochlear microphonic when vibration is applied to the ossicles by the probe; a database that stores a sensor voltage value output by the force sensor before surgical treatment, the potential value detected by the electrode, and surgical details; and a surgical details proposing unit that proposes selected surgical details on the basis of the magnitude of at least one of the sensor voltage value and the potential value measured before surgery with reference to the database.

Abstract: The method for producing a cell aggregate including glial progenitor cells according to the present invention comprises: (1) a step of subjecting pluripotent stem cells to suspension culture in an embryoid-body-forming culture medium containing one or more SMAD signaling inhibitors and one or more Wnt signaling activators in the absence of feeder cells for 5 days to 10 days, to form a cell aggregate; (2) a step of subjecting the cell aggregate obtained in (1) to suspension culture in an embryoid-body-forming culture medium containing retinoic acid; (3) a step of subjecting the cell aggregate obtained in (2) to suspension culture in an embryoid-body-forming culture medium or neuron-and-glia-proliferating culture medium containing retinoic acid and one or more SHH signaling activators; and (4) a step of subjecting the cell aggregate obtained in (3) to suspension culture in a neuron-and-glia-proliferating culture medium containing no retinoic acid and one or more SHH signaling activators.